# Why pharma AI pilots stall: data, talent and integration traps
A mid-size manufacturer spent 18 months and roughly $4 million building a computer vision system to catch defective tablets on a packaging line. In blind testing, it worked: 98% detection accuracy, praised in an internal town hall, greenlit for scale-up. Three years later it still runs on exactly one line, in one plant, watched over by the same two data scientists who built it. It never scaled. This is not a rare story. It is the median outcome.
Industry surveys, including work from McKinsey on AI in pharma manufacturing, consistently put the gap between pilots launched and pilots reaching full production at somewhere between 70% and 90% failure to scale, an estimate that varies by study but points the same direction. This lesson dissects why, using that stalled quality-control (QC, the process of verifying products meet specifications before release) rollout as the throughline.
The QC vision system was trained on 40,000 labeled images of tablets from one production line, one lighting rig, one camera angle. It worked beautifully there. The problems appeared the moment anyone tried to move it.
Trap 1: Data that doesn't travel. Line 2, in the same plant, used a different camera supplier and slightly different ambient lighting. Detection accuracy dropped from 98% to 71%. The model had learned the lighting conditions, not the defects. This is a classic case of overfitting to a narrow environment rather than learning a generalizable pattern. Nobody had budgeted for re-labeling and retraining at every new line, because the original business case assumed one build, infinite reuse.
Trap 2: No integration path into the quality system.
Trap 3: Validation cost was invisible in the original pitch. In pharma manufacturing, any system influencing batch release decisions falls under GMP (Good Manufacturing Practice, the FDA and EMA framework governing production quality) and is subject to computer system validation (CSV) requirements, and increasingly the FDA's Computer Software Assurance (CSA) guidance. Every retrain of the model potentially triggers a re-validation cycle. The original pilot budget covered building the model. It did not cover the recurring cost of proving, to auditors, that a periodically-updated AI system remains reliable.
Trap 4: The two data scientists became a single point of failure. No manufacturing engineer, no QC line supervisor, and no validation specialist owned the tool. When one data scientist left for another company, expansion plans quietly died. This is a talent and governance failure, not a technical one.
None of these traps are unique to quality control. The same four failure modes show up in AI applied to drug discovery, clinical trial site selection, and adverse event detection in pharmacovigilance (the science of monitoring drug safety post-approval).
Data fragmentation is structural, not incidental. Large pharma companies often run on decades of acquired systems: different electronic lab notebooks, different manufacturing execution systems (MES) across plants acquired in different eras, different data formats for clinical trial sites in different countries. An AI model trained on one subsidiary's clean dataset frequently cannot see, let alone use, another subsidiary's data without months of harmonization work. This is sometimes called the "data plumbing problem," and it is unglamorous, expensive, and almost never included in a pilot's original budget.
Talent sits in the wrong org chart position. Data scientists are frequently hired into IT or a central "digital innovation" team, disconnected from the regulatory affairs, quality, and manufacturing teams who must ultimately own and defend the system to auditors. When the pilot succeeds technically but nobody in quality or regulatory affairs was involved from day one, scale-up stalls because nobody with authority to approve GMP-relevant change is invested in the outcome.
Integration is treated as an afterthought, not a design constraint. A model that requires manual data export/import to function is a demo, not a production system. Real ROIROIReturn on Investment: the ratio of net profit to the cost of an investment. A 300% ROI means each dollar invested returns $3.Voir la définition complète → (return on investmentreturn on investmentReturn on Investment: the ratio of net profit to the cost of an investment. A 300% ROI means each dollar invested returns $3.Voir la définition complète →) requires the AI output to flow directly into decision systems, batch release software, trial management platforms, without a human manually bridging the gap every time.
Regulatory validation costs are underestimated by default. Under GMP and equivalent EU rules enforced by the European Medicines Agency (EMA), any AI system that influences a batch release, safety signal, or trial outcome decision needs documented evidence it performs consistently. That is not a one-time cost. Every model update, however small, can retrigger review. Pilots costed as one-time engineering projects, without a recurring validation budget line, are structurally set up to stall the moment they need updating.
Before greenlighting scale-up, ask four questions:
1. Portability: Has this been tested on data from a second site, line, or trial, not just the original training environment?
2. Ownership: Does someone in quality, regulatory, or operations (not just IT or data science) have formal accountability for this system's outcomes?
3. Workflow integration: Does the model's output feed automatically into an existing operational system, or does a human have to manually relay it?
4. Validation budget: Is there a recurring line item for re-validation when the model is retrained or updated?
A quick illustrative gut-check calculation: if a pilot costs $2 million to build and the organization has ten manufacturing sites, but scaling to each additional site requires $400,000 in re-labeling, integration, and re-validation (a plausible estimate, not a universal figure), the true program cost to reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.Voir la définition complète → full deployment is roughly $2M + (9 × $400K) = $5.6 million, nearly triple the number that appeared in the original pilot business case. Pilots that don't disclose this multiplier upfront tend to lose executive sponsorship the moment the real bill arrives.
# Rough scale-up cost estimator (illustrative only)
pilot_cost = 2_000_000
sites_remaining = 9
cost_per_site = 400_000
total_program_cost = pilot_cost + (sites_remaining * cost_per_site)
print(f"Estimated full rollout cost: ${total_program_cost:,}")
# Output: Estimated full rollout cost: $5,600,000Vérification des acquis
1. The QC vision system's accuracy dropped sharply when moved to a different line in the same plant. What does this reveal about the underlying problem?
2. Why is 'one build, infinite reuse' a risky assumption in a pharma AI business case?
3. The QC model's outputs sat in a standalone dashboard disconnected from the quality management system. What kind of trap does this represent?
4. Select ALL correct answers about why the majority of pharma AI pilots fail to scale to full production.
Sélectionnez toutes les réponses correctes.
5. Select ALL correct answers describing what made the original QC vision pilot appear successful before scale-up revealed its limits.
Sélectionnez toutes les réponses correctes.
Companies that successfully scale AI in regulated manufacturing tend to share a few habits, visible in public case discussions from firms like Novartis and GSK on their digital manufacturing initiatives.
They design for multi-site variability from day one, testing on data from at least two distinct environments before claiming success. They co-own the pilot across data science and quality/regulatory teams, so validation requirements shape the model architecture before it's built, not after. They budget for the full lifecycle, including recurring re-validation, not just initial build cost. And they integrate output directly into existing systems of record (the QMS, the MES, the trial management platform) rather than building a parallel dashboard nobody is required to check.
None of this is exotic. It is closer to standard project management discipline applied specifically to the regulatory and data realities of pharma. The technology in the stalled QC pilot was not the problem. The organization around it was.